A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.

NCT06928363 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

212

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: KY-0301

Sponsor

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.